Balance Sheet
Cash Flow Statement
AcquisitionsAmortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Dividends Paid - CommonFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based CompensationShares RepurchasedShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Viemed Healthcare (VMD) Cash from Financing Activities (2018 - 2025)

Viemed Healthcare's Cash from Financing Activities history spans 8 years, with the latest figure at -$8.5 million for Q4 2025.

  • For Q4 2025, Cash from Financing Activities fell 2191.83% year-over-year to -$8.5 million; the TTM value through Dec 2025 reached -$5.8 million, down 56.93%, while the annual FY2025 figure was -$5.8 million, 56.93% down from the prior year.
  • Cash from Financing Activities reached -$8.5 million in Q4 2025 per VMD's latest filing, down from $5.0 million in the prior quarter.
  • In the past five years, Cash from Financing Activities ranged from a high of $11.3 million in Q2 2023 to a low of -$8.5 million in Q4 2025.
  • Average Cash from Financing Activities over 5 years is -$1.4 million, with a median of -$1.5 million recorded in 2024.
  • Peak YoY movement for Cash from Financing Activities: surged 301.72% in 2023, then crashed 3535.9% in 2024.
  • A 5-year view of Cash from Financing Activities shows it stood at -$551000.0 in 2021, then plummeted by 783.85% to -$4.9 million in 2022, then soared by 37.78% to -$3.0 million in 2023, then soared by 113.33% to $404000.0 in 2024, then tumbled by 2191.83% to -$8.5 million in 2025.
  • Per Business Quant, the three most recent readings for VMD's Cash from Financing Activities are -$8.5 million (Q4 2025), $5.0 million (Q3 2025), and -$671000.0 (Q2 2025).